Gallo Center Scientists Identify Potential New Mechanism for Treating Problem Drinking
News Feb 25, 2013
The drugs, already approved for human use for other indications, reduced drinking and alcohol-seeking behavior in pre-clinical models — mice and rats trained to drink large quantities of alcohol.
The animals in the study, which was published today in the advance online edition of Translational Psychiatry, were trained to mimic so-called “problem drinkers,” not-yet-full-blown alcoholics, said senior author Dorit Ron, PhD, a Gallo Center investigator and a professor of neurology at UCSF.
“They consumed large quantities of alcohol and drank in binges, but were not yet physically dependent on alcohol,” she said. “In humans, these drugs could represent a promising new direction in preventing drinkers from going on to become fully addicted.”
The drugs, which inhibit enzymes called DNMT and HDAC, are currently being used to treat several types of cancer and show promise as medications for the treatment of mood disorders.
The study presents “a potential new mechanism to control excessive drinking,” said Ron.
The drugs act by modifying the structure of chromatin – a combination of DNA and proteins known as histones -- without affecting the composition of DNA itself, Ron said.
“Normally, changes on the DNA sequence called methylation lead to tightening of the chromatin structure, which prevents the expression of certain genes,” she said. “Conversely, a change in histones called acetylation leads to the opening of the DNA structure, allowing certain genes to be expressed.” DNMT inhibitors, which prevent methylation, and HDAC inhibitors, which promote acetylation, both act to loosen DNA structure, which in turn allows gene expression.
In the study, Ron and her research team trained mice to drink a solution of 20 percent alcohol. Mice that were given a DNMT inhibitor called 5-AzaC or HDAC inhibitors drank significantly less than mice that were not given the DNMT inhibitor.
Rats were also trained to self-administer drinks of alcohol by pressing a lever. Rats given SAHA, an HDAC inhibitor, showed significantly less alcohol-seeking behavior.
Importantly, in both mice and rats, the consumption of water, saccharine solution and sugar solution remained unchanged. “This means that these drugs specifically target alcohol without affecting the pleasure centers of the brain,” said Ron. “For people who have problems with alcohol, this would be a real improvement over current abuse medications, which suppress pleasure in general, leading to problems with compliance.”
Ron noted that alcohol use disorders represent a significant threat to public health worldwide, causing or being associated with a wide variety of physical and psychiatric illnesses. She called the study “an important example of pre-clinical, translational research, where findings in basic science lead straight to the possibility of clinical studies.”
Co-authors of the study are Vincent Warnault, PhD, and Emmanuel Darcq, PhD, of the Gallo Center and UCSF; Amir Levine, MD, of Columbia University; and Segev Barak, PhD, who was with Gallo and UCSF at the time of the study.
The study was supported by funds from the National Institutes of Health and the State of California through UCSF.
The UCSF-affiliated Ernest Gallo Clinic and Research Center is one of the world’s preeminent academic centers for the study of the biological basis of alcohol and substance use disorders. Gallo Center discoveries of potential molecular targets for the development of therapeutic medications are extended through preclinical and proof-of-concept clinical studies.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018